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Abstract
Background—The World Health Organization guidelines recommend cotrimoxazole
prophylactic treatment (CPT) for all HIV-exposed infants from age 6 weeks to the cessation of
breastfeeding and the exclusion of HIV infection. There are limited data about the effects of CPT
among this population of infants. We examined the effects of CPT on adverse health outcomes
among HIV-exposed infants during the first 36 weeks of life by using data from the Breastfeeding,
Antiretrovirals, and Nutrition (BAN) study, a large clinical trial of antiretroviral drugs given to the
mother or infant for prevention of HIV transmission during breastfeeding.
Methods—For the analysis, we assigned a status of CPT-exposed to infants who were
participating in the study after the CPT program started. We estimated unadjusted and adjusted
hazard ratios (HRs) for the effect of CPT status on time to incident malaria, severe illness or death,
anemia, and weight-for-age Z score < −2.0. Participation in the study was limited to focus
exclusively on HIV-exposed, uninfected infants.
Results—The HR for the effect of CPT on incident malaria was 0.35 (95% confidence interval
[CI]: 0.21, 0.57) during the first 10 weeks of CPT exposure, and 0.93 (95% CI: 0.67, 1.29) for the
remaining 20 weeks. CPT was not associated with the other outcomes examined.
Conclusions—CPT offered temporary protection against malaria among HIV-exposed,
uninfected infants. However, CPT offered no protection against anemia, low weight for age, or the
collapsed outcome of severe illness or death.
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More than 90% of new HIV infections among children are transmitted during pregnancy,
birth, or breastfeeding.1 During the past decade, increasing access to perinatal interventions
to prevent mother-to-child transmission of HIV has resulted in a growing number of infants
who are exposed to HIV, but remain uninfected. These HIV-exposed, uninfected (HEU)
infants face ongoing risk of acquiring HIV through breastfeeding. In addition, these infants
may be at increased risk of acquiring other infections from close contact with
immunodeficient members of their household who may be colonized with diverse
pathogens.2–4 Malaria and HIV infections overlap geographically across much of sub-
Saharan Africa, further illustrating the ongoing threat to the health of HIV-exposed
children.5 Children younger than five years old generally experience the highest rate of
malaria, and these children are especially vulnerable to infection during the first two years of
life. The peak age of infection is inversely related to the intensity of malaria transmission—
infants are more affected in high transmission areas.6
The World Health Organization (WHO) recommends daily cotrimoxazole prophylactic
treatment (CPT) for infants born to HIV-infected mothers, from 6 weeks to the cessation of
breastfeeding and the exclusion of infant HIV infection.7 Because of the difficulty and cost
of diagnosing HIV-exposed infants early in many resource-limited settings, the WHO CPT
guideline serves to protect infants who have undiagnosed HIV infection from other
opportunistic infections. This WHO recommendation is based on the results of randomized
controlled trials (RCTs) and non-experimental studies that demonstrated decreased
incidence of severe events, hospitalizations, and death among HIV-infected adults and
children.8–13 Specifically, the use of CPT among HIV-infected adults and children has been
associated with reductions in the incidence of malaria.8, 14, 15
Very limited data are available to demonstrate the beneficial effects of CPT among HEU
infants.16, 17 Even though malaria is the primary cause of death among African children
younger than 5 years,18 there are no data about the effectiveness of CPT to reduce the
incidence of malaria among HEU infants during the first few months of life. A better
understanding of the effects of this widely recommended regimen on the incidence of poor
health outcomes is important among an extremely vulnerable population. In the present
analysis, we examine the effects of CPT on adverse health outcomes among HEU infants
during the first 36 weeks of life.
METHODS
Study Design and Population
All children were enrolled in the randomized and controlled Breastfeeding, Antiretrovirals
and Nutrition (BAN) trial, which took place at 4 clinics in Lilongwe, Malawi, during 2004–
2009.19 The BAN study design and primary findings have been reported elsewhere and have
shown that the use of either maternal antiretroviral drugs or infant nevirapine for 28 weeks
was effective in reducing HIV transmission during breastfeeding.19, 20 HIV-infected,
pregnant women who were 14 years or older, naïve to antiretroviral therapy (ART, and had
reached 30 weeks or less of gestation were eligible for enrollment, if they had hemoglobin
levels higher than 7 g/dL, CD4 cell counts of 250 cells/μL or higher (≥200 cells/μL before
July 24, 2006), normal liver function tests (ALT < 2.5x the upper limit of normal), and no
serious pregnancy complications.
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If mother-infant pairs met secondary eligibility criteria, they were randomized within a week
of birth to a 2-group maternal nutritional intervention and to a 3-group antiretroviral
intervention consisting of a 3-drug antiretroviral regimen for the mother (maternal-regimen
group), a daily dose of nevirapine for the infant (infant-regimen group), or neither (control
antiretroviral group). The interventions began after delivery and were continued until the
cessation of breastfeeding, but no longer than 28 weeks. Infants found to be HIV-infected at
birth or in the first 2 weeks of life were disenrolled from the BAN study and referred for
care. Infants who tested positive for HIV infection later than 2 weeks of life, which was the
primary endpoint of the BAN study, were discontinued from the intervention but not
disenrolled from the study, and were encouraged to continue attending regular study visits.
Mother-infant pairs were seen for visits at delivery and at 1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 32,
36, 42 and 48 weeks postpartum. Data capturing anthropometrics, vital signs, illnesses and
hospitalizations since the last visit, current symptoms, and physical exam findings were
collected at all follow-up visits. Blood was collected at 2, 4, 6, 12, 18, 24, 28, 36 and 48
week visits. Participants were advised to return to the clinic between visits to receive
treatment if the woman or child was ill.
In accordance with the Malawi Ministry of Health and Population Guidelines and WHO
guidelines on cotrimoxazole prophylaxis,7 CPT was initiated in the BAN study for eligible
women and infants in 2006; prior to 2006, the WHO and UNAIDS had not published CPT
guidelines for resource-limited settings. Starting on 13 June 2006, CPT (240 mg once daily)
was provided to all infants in the BAN study beginning at 6 weeks of age. Infants, who
stopped breastfeeding by 28 weeks of age and were also HIV-uninfected at 28 weeks,
continued CPT until age 36 weeks. Infants who did not wean by 28 weeks continued CPT
until weaning occurred and HIV infection was ruled out. CPT for children who were HIV-
infected was intended to be life-long and was provided for the duration of participation in
the BAN study. CPT was also initiated at the same time for mothers who had a CD4 cell
count less than 500 cells/μL, as measured during pregnancy or at 24 weeks post partum.
For the purpose of this analysis, we excluded infants who did not present for a visit between
6–8 weeks of age and who did not have at least one follow-up visit after that time. Infants
diagnosed with HIV infection at or before the 6 week visit were not included in the analysis.
Ethical review
The BAN study protocol was approved by the Malawi National Health Science Research
Committee and the institutional review boards at the University of North Carolina at Chapel
Hill and the U.S. Centers for Disease Control and Prevention.
Statistical Analysis
All statistical analyses were performed using SAS (version 9.2, SAS Institute, Cary, NC).
Descriptive analyses included calculation of frequencies and medians of exposures,
outcomes and covariables. Categorical proportions were compared using chi-square test and
continuous variables were assessed using the Wilcoxon rank-sum test.
We estimated unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals
(CIs) for the effect of CPT status on time to (1) first infection with malaria, (2) first severe
illness or death, (3) anemia, or (4) low weight for age. For each of these four outcomes, we
began with separate bivariate models containing only CPT and the outcome of interest.
Multivariable models were then constructed including covariables associated with CPT or
the outcome of interest. We examined the proportional hazard assumption graphically using
log-log plots and by adding interactions with time to the model. If the assumption was
violated, it was relaxed by fitting interactions with categorical or continuous time.21 We
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explored rainy season, antiretroviral study arm, infant age and first pregnancy as modifiers
of the association between CPT and the outcomes of interest.22 Covariables found to be
important effect measure modifiers were included in the starting multivariable model
through an interaction term with CPT exposure status. To construct final models, we used a
manual, backward elimination, change-in-estimate strategy. Potential confounders were
removed from the preliminary full model in order of p-value magnitude (covariables with
the highest p-values were removed first). If the CPT-outcome association changed by less
than 10% overall or in any stratum of an interacting variable, a given covariable was not
retained.23
For time-to-event analyses, children who tested positive for HIV were censored at the last
visit at which they tested negative. Infants were also censored at death, maternal death, or
loss to follow-up.
Definitions
The unanticipated change in CPT guidelines and their implementation 2 years into the BAN
study created a natural experiment, with a CPT-unexposed period followed by a CPT-
exposed period. Therefore, for the purpose of this analysis, exposure to CPT was based on
the 2006 time-point at which standardized CPT was implemented in the BAN study. To
minimize misclassification of CPT, inclusion in our analysis was restricted according to 3
criteria. First, in order to account for any lag time between the decision to administer CPT
and the routine implementation of this practice, person-time from infants presenting for a
visit between 6–8 weeks of age between 13 June 2006 (the date the first infant was started
on CPT) and 15 August 2006 was not included in these analyses. Second, infants were only
included if they presented between 6–8 weeks of age, to ensure that all infants were started
on CPT within a 2 week age window. Finally, to avoid mixed exposure, analyses only
included children who were either never exposed to CPT (fully unexposed, age 36 weeks by
June 13, 2006), or children who were exposed to CPT from 6–8 weeks of age onward (fully
exposed, age 6 weeks on or after August 15, 2006).
Malaria was defined by the first episode of infection after 6 weeks of age and was diagnosed
as a positive blood smear from a child arriving with symptoms of malaria. We excluded
children who had a diagnosis of malaria before 6 weeks. Severe illness was defined by the
first event after 6 weeks of diarrhea, malaria, meningitis, pneumonia, or serious febrile
illness that was fatal or life-threatening, required inpatient hospitalization, or resulted in
persistent or significant disability or incapacity. Anemia was defined by a hemoglobin level
below 7 g/dl from 6 to 8 weeks, or below 9 g/dl after 8 weeks of age, according to toxicity
tables (revised March 2006) from the Division of AIDS at the National Institute of Allergy
and Infectious Diseases (NIAID). Malnutrition was classified on the basis of weight-for-age
Z scores (WAZ) that were calculated by using the January 2011 WHO Child Growth
Standards macros (version 3.2.2).24 An infant was considered undernourished if the WAZ
was less than −2.0 after 6 weeks of age. The rainy season was defined as the period from
November to March and analyzed as a time-varying covariable. In addition, the rainy season




After excluding 387 infants with mixed CPT exposures and 19 infants who were diagnosed
with HIV at or before the 6-week visit, 1,522 mother-infant pairs, representing
approximately two-thirds of the BAN cohort, were eligible for analysis (see Table,
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Supplemental Digital Content 1, http://links.lww.com/INF/B207). Mothers of infants
exposed to CPT were slightly older (26 vs. 25 years) and more likely to be married (92.6%
vs. 89.1%). Mothers of CPT-exposed infants had an insignificantly higher CD4 cell count
(441.0 vs. 431.0 cells/μL). Accounting for censoring at HIV infection, death, loss to follow-
up, or the 36-week visit, the median duration of follow-up from the 6-week visit was 188
and 189 days among the CPT-exposed and unexposed groups, respectively.
Effect of CPT on Time to Adverse Health Outcomes
Thirty-four infants had malaria before 6 weeks of age and were not included in the time-to-
event analysis examining the association between CPT and incident malaria. We observed
311 cases of infant malaria prior to 36 weeks of age (and prior to censoring due to HIV
infection, death, or loss to follow-up) (Table 1) (Figure 1). The unadjusted HR for the effect
of CPT exposure on time to incident malaria was 0.71 (95% CI: 0.55, 0.93). As evidenced
by the log-log plot and the statistical significance of a continuous interaction term with time
in the multivariable model, the effect of CPT appeared to change over time. Therefore, a
categorical time interaction term at 70 days after initiation of CPT, corresponding to 16
weeks of age, was included in the model. This time-stratified analysis yielded an HR of 0.35
(95% CI: 0.21, 0.57) for the effect of CPT on incident malaria from 6 to 16 weeks and an
HR of 0.94 (95% CI: 0.68, 1.30) from more than 16 to 36 weeks of age. Additional
covariables did not meet the a priori criteria set for inclusion in the final model, and, thus,
our final model for the outcome of malaria included only CPT and a categorical interaction
term at 70 days after initiation of CPT.
We observed 169 severe illnesses or deaths among eligible infants (Table 1) (Figure 1).
Pneumonia was the most common (33.1% of all events), followed by diarrhea (27.2%). The
unadjusted HR for the effect of CPT exposure on time to severe illness was 0.92 (95% CI:
0.63, 1.34). None of the covariables met our criteria for effect measure modification or
confounding of the effect of CPT on this outcome.
Anemia was documented in 49 CPT-unexposed infants and 166 CPT-exposed infants (Table
1) (Figure 1). The unadjusted HR for the effect of CPT exposure on time to anemia was 0.78
(95% CI: 0.58, 1.05). No covariable met our criteria for inclusion in the final model.
Low WAZ occurred in 46 CPT-unexposed and 192 CPT-exposed infants (Table 1) (Figure
1). The HR for the effect of CPT exposure on time to low weight for age was 0.97 (95% CI:
0.72, 1.34). With adjustment for baseline weight (at 6 weeks of age), the direction of the
association was reversed (adjusted HR 1.18, 95% CI: 0.83, 1.67) but continued to be weak
and not statistically significant. No other covariable met our criteria for inclusion in the final
model.
Regarding possible CPT-related toxicities, CPT was not associated with more frequent
severe cases of rash or neutropenia, however, there was a single case of asymptomatic
severe anemia which was designated as possibly due to cotrimoxazole.20
DISCUSSION
Our results indicate that CPT may provide temporary protection against malaria in HEU
infants during early infancy, but CPT provides no protection against anemia, low weight for
age, and severe illness or death. Previous studies have shown that CPT protects against
malaria in HIV-infected adults and children10, 14 and older HIV-uninfected children (aged
5–15 years).12 In one RCT, in which all infants were also provided with insecticide-treated
bed nets (ITNs), HIV-exposed infants who continued CPT until 2 years of age, after
cessation of breastfeeding and exclusion of HIV infection, had a 39% reduction in malaria
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incidence compared with infants who stopped CPT after cessation of breastfeeding at a
median age of 10 months.25 We explored an earlier age period and found that CPT was
associated with a 65% reduction in malaria episodes from 6 to 16 weeks (adjusted HR of
0.35 (95% CI: 0.21, 0.57)), but we did not observe a protective effect after 16 weeks of age.
The effect of CPT among infants, particularly during the first months of life, may be
complex. Malaria is more commonly seen after the first 2–3 months of life, when maternal
antibodies wane,26 with incidence generally peaking within the first 2 years, especially in
areas of high transmission.26, 27 Maternal HIV infection has been demonstrated to
negatively affect the transfer of some maternal antibodies28, 29 and is believed to affect the
development of the immune system in utero.30, 31 These factors may cause HIV-exposed
infants to be more susceptible to malaria and other infections during the first few months of
life, when passive immunity usually provides protection, and when the infant’s immune
system is still developing. Alternatively, there may be a synergistic interaction between CPT
and existing maternal antibodies during the first few months of life, resulting in additional
protection against malaria for the infant.
CPT was not significantly associated with reduced likelihood of grade 3 or 4 anemia,
although we observed a protective trend among these Malawian infants. Observed
associations between CPT and anemia in the literature are mixed. Protection against anemia
was observed among healthy children (aged 5–15 years) receiving CPT, which may be
secondary to the observed protection from malaria.12 In HIV-infected adults with a CD4 cell
count of at least 500 cells, CPT had no effect on hemoglobin.32 The most applicable data
come from a recent study of the effects of nevirapine and CPT in infants, where no increased
risk of grade 3 or greater anemia was found.33
In the current study, CPT did not protect against severe illness, death, or low weight for age.
In contrast, other studies have reported that CPT protects against death and respiratory
infections among HIV-infected children,34 respiratory infections among HIV-infected
infants,16 and gastrointestinal illness among older healthy children.12 We did not observe an
effect of CPT on severe illness and death, but because of the small number of events, we
were unable to assess associations between CPT and specific infections. Repeated measures
analysis of the effects of cotrimoxazole on specific serious adverse events using the full
BAN cohort is currently underway and will help to provide further insight into the effects of
CPT on specific health outcomes, rather than the collapsed outcomes examined here.
Exclusive breastfeeding, particularly in the first 6 months, is associated with protection from
malnutrition and infectious disease among infants.35 Also, because of the lipid-based
nutrient supplement provided to infants after cessation of breastfeeding in the BAN study,
our analysis population may exhibit less variation in nutritional outcomes than what might
be observed outside of this clinical trial setting. Therefore, it is possible that the protective
effects of CPT against these outcomes would become more apparent in the context of
replacement or mixed feeding. Benefits of CPT may also be more apparent when assessing
all morbidity, including mild infections. However, a recent study of breastfeeding HEU
children showed no protection of CPT against lower respiratory tract infection, with a trend
toward increased incidence of diarrhea, though the association did not reach statistical
significance (incidence rate ratio of 1.38 (95% CI: 0.98, 1.94)).36
Our analyses have important limitations that are similar to other observational studies. First,
exposure status was based on presumed exposure by using the 2006 date that CPT was
initiated in the BAN Study. A review of a random sample of patient pharmacy records
showed good adherence to the CPT guidelines (data not shown). However, it is possible that
some children classified as exposed may not have taken cotrimoxazole, which could bias our
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results. If this is the case, our observed estimates are likely weaker than the true magnitude
of the effect of CPT on the outcomes of interest.
Second, unmeasured changes among the population during the more than 5 years of
observation (2004–2009) may have coincided with the rollout of CPT (mid-2006). Temporal
changes in disease incidence occurring during the study period cannot be separated from the
effects of CPT. For example, starting in March 2007, ITNs were distributed to 3,500 HIV-
infected pregnant women in Lilongwe, including some of the women participating in the
BAN study. ITN use was unmeasured. If malaria decreased because of the use of ITNs or
other factors, the protective effect in the first 16 weeks of life suggested by our analysis may
be an artifact of ITN use or other changes in disease incidence unrelated to CPT. In addition,
it is possible that the simultaneous initiation of CPT in BAN mothers with a CD4 cell count
of less than 500 cells/μL could have contributed to the protective effect against malaria
demonstrated in our analyses.3 It is also possible that the small number of CPT-unexposed
infants may have limited our ability to detect differences between groups. As noted earlier,
suboptimal adherence likely occurred in our study because we did not monitor adherence to
CPT. However, suboptimal adherence also would occur outside of a study setting, and our
study may thus approximate the normal conditions of varied adherence observed in routine
rollout of CPT, which strengthens the generalizability of our findings. A final limitation was
that malaria smears were not independently reviewed by a second person.
The primary rationale for CPT among HIV-exposed infants is to reduce death and disease
from opportunistic infections among HIV-infected infants whose HIV statuses have not yet
been determined. Following current WHO guidelines, it is no longer ethical not to
administer CPT to HIV-exposed infants. Thus, the conduct of an RCT to examine the effect
of CPT in HEU infants is not possible. Observational studies, such as this one, may be the
only means of providing valuable insight into the effects of CPT among HEU infants. The
incidence of infant HIV infection is declining with the use of effective preventive
interventions. In addition, infants with HIV infection are diagnosed more quickly due to
widely available HIV testing, allowing for more timely interventions to prevent
opportunistic infections. Further study of the role of infant CPT in the current context of
pediatric HIV should be conducted to ensure the best use of limited resources to protect the
health of this vulnerable population.
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Kaplan-Meier curves illustrating the probability of event-free survival for (A) malaria, (B)
severe illness or death, (C) moderate or severe anemia, and (D) weight-for-age Z score < -2.
Red represents infants exposed to CPT; black represents infants unexposed to CPT.
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TABLE 1
Frequency of Outcomes of Interest from 6 to 36 Weeks of Age in CPT-Exposed and Unexposed Infants in
Lilongwe, Malawi, During 2004–2009.
Outcome CPT-unexposed infants* (n =
283)
CPT-exposed infants* (n = 1,239) Total (N = 1,522) P-value
Malaria (any severity) 70 (24.7%) 241 (19.5%) 311 (20.4%) 0.03
Anemia 49 (17.3%) 166 (13.4%) 215 (14.1%) 0.08
Severe illness or death 34 (12.0%) 135 (10.9%) 169 (11.1%) 0.59
 Diarrhea 11 (3.9%) 35 (2.8%) 46 (3.0%)
 Malaria(severe) 10 (3.5%) 14 (1.1%) 24 (1.6%)
 Meningitis 1 (0.4%) 9 (0.7%) 10 (0.7%)
 Pneumonia 5 (1.8%) 51 (4.1%) 56 (3.7%)
 Febrile illness 6 (2.1%) 22 (1.8%) 28 (1.8%)
 Vomiting 0 (0.0%) 2 (0.2%) 2 (0.1%)
 Death 1 (0.4%) 2 (0.2%) 3 (0.2%)
Low weight for age (Z score < -2) 46 (16.3%) 192 (15.6%) 238 (15.6%) 0.75
*
Infants were considered CPT-unexposed if > 36 weeks of age by June 13, 2006; infants were considered CPT-exposed if they reached 6 weeks of
age on or after August 15, 2006.
†
 P-value based on chi-square test comparing CPT-exposed and CPT-unexposed groups. CPT = cotrimoxazole preventive therapy
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